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Objectives: Due to the lack of direct head-to-head trials, there are limited data regarding the compar-
ative effectiveness of induction-maintenance sequences. The objective of this study was to develop a
cost-effectiveness model to compare induction-maintenance sequences in the US for the treatment of
advanced non-squamous NSCLC.
Materials andmethods:Decision analyticmodellingwas used to synthesize the treatment effect and base-
line risk estimates for nine induction and maintenance treatment sequences, reﬂecting treatments used
in the US. The model was structured using an area-under-the-curve approach and sensitivity analyses
were conducted. Model validation was conducted by an independent third party.
Results: All active maintenance therapy-containing regimens, with the exception of gemcitabine +
cisplatin (ﬁrst-line)→ erlotinib (maintenance), were more costly than induction-only regimens. Con-
cerning treatments that may be cost effective, the incremental costs per life-year gained were $121,425,
$148,994, and $191,270 for gemcitabine + cisplatin→ erlotinib versus gemcitabine + cisplatin→best
supportive care (BSC), pemetrexed+ cisplatin→BSC versus gemcitabine + cisplatin→ erlotinib, and for
pemetrexed+ cisplatin→pemetrexed versus pemetrexed+ cisplatin→BSC, respectively. All other regi-
mens were found to be dominated (carboplatin +paclitaxel→BSC; carboplatin +paclitaxel→ erlotinib;
carboplatin +paclitaxel→pemetrexed; bevacizumab+ carboplatin +paclitaxel→bevacizumab) or
extendedly dominated (cisplatin + gemcitabine→pemetrexed). Sensitivity analyses demonstrated
stability.
Conclusions: Depending on the speciﬁc cost-effectiveness threshold used by a decision maker, the
most cost-effective treatment sequence may include the referent comparator gemcitabine + cisplatin
and the studied regimens of gemcitabine + cisplatin→ erlotinib, pemetrexed+ cisplatin→BSC, or peme-
trexed+ cisplatin→pemetrexed.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC. Introduction
Lung cancer is the overall leading cause of cancer-related death
n the US, despite the fact thatmore breast and prostate cancers are
iagnosed each year [1]. The prognosis for non-small cell lung can-
er (NSCLC) patients is poor, with only 21.4% of patients surviving
ve years or longer [2]. Progress in lung cancer has demonstrated
he least improvement in survival outcomes among cancers from
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1975 to 2009 [1]. In recent years, the treat-to-progression strategy
has emerged, demonstrating signiﬁcant improvements in overall
survival of maintenance regimens utilizing single-agent therapy of
pemetrexed, erlotinib or bevacizumab.
There are limited head-to-head clinical trial data of various
treat-to-progression strategies to support evidence-based deci-
sion making. The studies that have demonstrated signiﬁcant
OS beneﬁt with different single-agent maintenance treatments
have not been directly compared [3–5]; as a result, there are
limited data regarding the comparative effectiveness and subse-
quent cost-effectiveness of the available induction-maintenance
sequences.
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Table 1
Comparators included in the model and selected trials from the network meta-
analysis by Woods et al. [6].
Induction (I); and Maintenance (M) regimens
I: Cisplatin +pemetrexed; M: pemetrexedb
I: Cisplatin +pemetrexed; M: best supportive care (BSC)b
I: Cisplatin + gemcitabine (1000mg/m2); M: BSCa
I: Cisplatin + gemcitabine (1000mg/m2): M: erlotiniba
I: Cisplatin + gemcitabine (1000mg/m2): M: pemetrexedb
I:bevacizumab (15mg) + carboplatin +paclitaxel; M:bevacizumab (15mg)b
I:carboplatin +paclitaxel: M:erlotinib
I:carboplatin +paclitaxel; M: pemetrexed
I:carboplatin +paclitaxel; M: BSC
Key clinical trials
Sandler et al. Bevacizumab+ carboplatin +paclitaxel vs carboplatin +paclitaxel
[10]
Scagliotti et al. Pemetrexed+ cisplatin vs gemcitabine + cisplatin (JMDB) [9]
Carboplatin +paclitaxel vs carboplatin + gemcitabine [13]
Schiller et al. Cisplatin + gemcitabine vs carboplatin +paclitaxel vs
docetaxel + cisplatin [24]
Perol et al. Gemcitabine + cisplatin followed by maintenance erlotinib or
gemcitabine vs best supportive care [25]
Paz-Ares et al. Maintenance pemetrexed vs best supportive care [11,26]
Cappuzzo et al. Maintenance erlotinib vs best supportive care [5]
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ma Regimen is FDA-approved for use in NSCLC.
b Regimen is FDA-approved for use in non-squamous NSCLC.
. Materials and methods
.1. Overview
This US cost-effectiveness analysis (CEA) was adapted from a
lobal/international model [6] by restricting the comparator ther-
pies to regimens used in the US and by applying US-speciﬁc
osts, and resource use. The nine comparator sequences provided
n Table 1 were selected based on regimens included in National
omprehensive Cancer Network guidelines. A no-treatment option
as not considered to be a valid alternative in patients willing/ﬁt
nough to undergo chemotherapy; therefore, no calculations were
erformed to test the cost-effectiveness of the referent regimen of
emcitabine + cisplatin without maintenance.
However, itwas assumed that this referentmay be cost effective
n the US based on prior research supporting this regimen as a cost-
ffective treatment alternative in the UK [28].
The commonly-used ﬁrst-line pemetrexed+ carboplatin regi-
en was not included in the CEA due to the lack of sufﬁcient
omparative clinical trial data [7,8]. It has been suggested that car-
oplatin and cisplatin are comparable in terms of efﬁcacy and that
arboplatin may be less toxic [7]. The primary measure of effec-
iveness in the model is life-years gained. Both progression-free
urvival (PFS) and overall survival (OS) endpoints are modelled as
FS is predictive of costs, in particular the costs associated with
ubsequent lines of therapy.
The model was implemented as an area under the curve model.
he model simulates patients moving through three health states:
re-progression, post-progression and death with mortality being
odelled as all-cause mortality. The model uses a cycle length of
neweek; threemodel cycles equals one 21-day treatment cycle. A
0-year lifetime horizon was implemented in the model at which
ime it was assumed that the cohort of lung cancer patients would
ave progressed to death. Costs and beneﬁts were discounted at
.5% per annum. The costs in the study were calculated in 2013
ollars..2. Modelling of PFS and OS
Decision analytic modelling was used to synthesize the treat-
ent effect and baseline risk estimates accounting for the differentr 89 (2015) 294–300 295
patient populations included in the induction and maintenance
treatment trials.
Gemcitabine + cisplatin was selected as the baseline induction
treatment due to its frequent use and the availability of individual
patient data and efﬁcacy data from the registration trial supporting
pemetrexed maintenance therapy (JMDB trial) [9]. Patients within
the JMDB trial were classiﬁed as eligible or ineligible for mainte-
nance treatment andoutcomeswere estimated separately for these
patient groups. Patients were classiﬁed as eligible for maintenance
if they had completed four cycles of treatment, were progres-
sion free, and presented with an ECOG performance status score
between 0 and 1. All other patients were classiﬁed as ineligible for
maintenance. This rule corresponded to 63.5% of ﬁrst-line patients
being eligible for maintenance.
The PFS and OS hazard ratios for the selected US regimens
were obtained from a network meta-analysis (NMA) (Table 2) [6].
The treatment effects for induction and maintenance were applied
to estimates of the baseline risk of each event type (the risk of
experiencing progression or death), obtained from the re-analysis
of cisplatin + gemcitabine data from the JMDB trial [9]. Due to
the design of the bevacizumab trials (i.e., treat until progression)
[10], PFS and OS outcomes for induction and maintenance of this
regimen are not available separately. The treatment effect of main-
tenance is assumed to be independent of induction treatment, with
the exception of pemetrexed, where separate treatment effects for
pemetrexedmaintenance are used for ‘switch’ (maintenance agent
is different than what is used ﬁrst line, from the JMEN trial) versus
‘continuation’ (maintenance includes one of the ﬁrst-line agents,
from the PARAMOUNT trial).
2.3. Treatment pattern assumptions
The induction period is assumed to be four cycles if peme-
trexed or erlotinib are used for maintenance therapy, based on
the design of the phase III trials [5,11]. To reﬂect usual practice,
for patients not allocated onto active maintenance, the length
of the induction period is assumed to be the mean number of
cycles reported in the largest trial available for the given induc-
tion treatment. For triplet sequences, it was assumed that after
a patient completes induction on a triplet induction therapy (for
the duration observed in the bevacizumab trials), the patient will
be eligible to continue to receive monotherapy with the biologic
component of the therapy, consistent with the bevacizumab trials
[3,12].
Patients receiving maintenance treatment are assumed to
receive treatment from the end of induction until either disease
progression or maintenance treatment discontinuation for other
reasons. Discontinuation for other reasons was estimated from
the pemetrexed arm of the PARAMOUNT trial, this estimate was
assumed to apply to all maintenance treatments.
2.4. Statistical analysis
The induction and maintenance network meta-analysis results
for the ﬁxed effectsmodels were used as thesewere preferred over
random effects models in all cases [6].
Baseline risk estimates for the JMDB trial were estimated using
Kaplan Meier curves for the within trial period and parametric
survival models for the post-trial period. Separate survival curves
were estimated for patients eligible and ineligible for mainte-
nance. Four different parametric curves were ﬁtted to the survival
data: Weibull, exponential, log-normal, and log-logistic. For all
analyses the best-ﬁtting parameterization was identiﬁed by the
Akaike Information Criterion (AIC) score (a statistical measure for
“goodness of ﬁt”), a visual assessment of the ﬁtted curves, and
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Table 2
Progression free survival (PFS) and overall survival (OS) hazard ratios (HR) and 95% credible intervals (CI) for ﬁrst-line and maintenance regimens included in the model [6].
Pooled First-line induction regimens Fixed effects
PFS HR (vs. cisplatin + gemcitabine) 95% CI
Cisplatin +Pemetrexed 0.899 0.788–1.019
Carboplatin +Paclitaxel 1.111 0.939–1.306
Bevacizumab+Carboplatin +Paclitaxel 0.729 0.585–0.899
Pooled First-line induction regimens Fixed effects
OS HR (vs. cisplatin + gemcitabine) 95% CI
Cisplatin +Pemetrexed 0.811 0.700–0.940
Carboplatin +Paclitaxel 1.055 0.900–1.237
Bevacizumab+Carboplatin +Paclitaxel 0.865 0.699–1.069
Pooled Maintenance regimens Fixed effects
PFS HR (vs. best supportive care) 95% CI
Pemetrexed 0.55 0.47–0.64
Erlotinib 0.76 0.68–0.84
Pooled Maintenance regimens Fixed effects
OS HR (vs. best supportive care) 95% CI
Pemetrexed 0.74 0.64–0.87
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onsiderationof theplausibility of the extrapolations generated [4].
he baseline risk model ﬁtting was performed using SAS version
.2. This modeling work was separately conducted for the survival
stimates [6].
.5. Costs
Treatment costs are presented in Table 3. Patients who receive
aintenance treatment have induction acquisition and adminis-
ration costs assigned to all progression-free patients for up to six
ycles for bevacizumab triplet induction and up to four cycles for
ll other induction treatments (until maintenance), as observed in
linical trials [9,13,14]. Drug costs per patient have been calculated
y taking the minimum number of vials of different size required
o achieve the desired dose thereby limiting the excess accrual of
edication costs. A sensitivity analysis was programmed into the
odel to evaluate medication costs for only the actual amount of
edication administered, reﬂecting an efﬁcient use of resources
no wastage).
Hospitalization costs were stratiﬁed into pre-progression and
ost-progression costs. The proportion of patients hospitalized and
he length of stay have been calculated from the BSC arm of the
ARAMOUNT trial [11]. The cost for a CT scan is allocated to a pro-
ortion of the patients at risk of progression. Similarly, the cost of
physician visit is allocated to a proportion of patients at all points
n the model. Weekly probabilities were applied to the allocation
f radiotherapy delivery and preparation costs. Resource use for CT
cans and physician visits was based on regional practice patterns;
adiotherapy resource use was estimated from the PARAMOUNT
rial. Concomitant medication use is also included in the model
sing data from the PARAMOUNT trial. A terminal care cost is
llocated when a patient dies and is assumed to be equivalent
egardless of prior treatment.
A proportion of patients who experience disease progression
as assumed to receive a second-line therapy drug from theollowing: docetaxel, erlotinib, gemcitabine, vinorelbine, pacli-
axel and pemetrexed, depending on the initial line of therapy.
hese proportions were derived from a study of ﬁrst- and second-
ine healthcare utilization and costs of patients with NSCLC the0.78–0.96
SEER-Medicare Database [15]. The proportion of patients expe-
riencing each adverse event was obtained from the largest trial
available for each treatment.
2.6. Presentation of results
A treatment is labelled as “dominated” if another treatment
has lower costs and better or equivalent outcomes. A treatment is
labelled as “extendedly dominated” when it is less effective and
has a higher incremental cost-effectiveness ratio than an alter-
native treatment. These comparators do not represent value for
money and are removed from themodel calculations in accordance
with international standards for the conduct of cost-effectiveness
research [16]. All other regimens provide an incremental cost-
effectiveness ratio (ICER) against the next best option. A decision
maker should select the treatment with the highest ICER that falls
below their cost-effectiveness threshold.
2.7. Sensitivity analyses
A series of one-way sensitivity analyses were performed to
address uncertainty, including changing the baseline risk paramet-
ric functions toWeibull for OS and log-logistic for PFS; changing the
baseline risk parametric functions to log-logistic for both OS and
PFS; maintenance ineligible patients receive 50% of the induction
treatment effect; ineligible patients receive 100% of the induction
treatment effect; using the pooled hazard ratio (HR) from the net-
workmeta-analysis for pemetrexedmaintenance; using aﬁve-year
time horizon; turning the treatment effect off at 32 months for
induction (JMDB follow up period); and 34 months for mainte-
nance (PARAMOUNT follow up period); assuming no wastage; and
restricting the comparator list to therapies that are FDA approved
for use in NSCLC.
A probabilistic sensitivity analysis (PSA) was conducted to esti-
mate the level of conﬁdence in the conclusions of this economic
evaluation. Distributions were assigned to all model inputs, 1000
simulations were run, and the results were plotted. The amount of
scatter or spread around the model-derived ICER is used to assess
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Table 3
Summary of costs included in the model.
Drug Unit size (mg) Price per unit Source
Pemetrexed 500 $2897.50
Red Book, 2013 [29]
Pemetrexed 100 $579.50
Erlotinib 150 $191.73
Erlotinib 100 $169.51
Erlotinib 25 $61.72
Paclitaxel 300 $46.67
Paclitaxel 150 $66.00
Paclitaxel 100.2 $18.32
Paclitaxel 30 $8.26
Docetaxel 160 $1465.75
Gemcitabine 1000 $44.63
Gemcitabine 2000 $99.00
Gemcitabine 200 $9.30
Gemcitabine 38 $8.93
Vinorelbine (second line) 50 $90.00
Vinorelbine (second line) 10 $18.00
Bevacizumab 400 $2483.56
Bevacizumab 100 $620.89
Cisplatin 100 $34.00
Carboplatin 150 $10.52
Administration costs Mean CPT Code Source
Initial infusion (up to 1 hour) $ 230.50 96413
Centers for Medicare and Medicaid Services, 2013.[30]Additional hour(s) $ 39.13 96415
Subsequent infusion $ 74.69 96417
Adverse Events (grade 3/4) Mean SE ICD-9 Code Source of cost data
Leukopenia $ 8891.75 $ 1173.66 288.50
Hospital charges from HCUPnet (2013). Inﬂated from 2011
$US to 2013 $US using the medical care component of the
Consumer Price Index (US Bureau of Labor Statistics, 2013).
Thrombocytopenia $ 16488.48 $ 601.43 287.31
Neutropenia $ 12006.35 $ 542.13 288.00
Febrile neutropenia $ 12006.35 $ 542.13 288.00
Anemia $ 6810.63 $ 141.56 280.90
Infection (granulocytopenia) $ 12712.76 $ 1084.93 288.09
Fatigue/Asthenia $ 6304.42 $ 122.83 780.79
Nausea/Vomiting $ 6160.95 $ 130.99 787.01
Acne-like rash $ 4482.32 $ 325.37 692.90
Supportive Care Drugs Number of tablets
or vials per pack
mg of drug per
tablet/vial
Pack Price Source
Alprazolam 100 0.25 $ 3.34
Red Book, 2013 [29]
Amoxicillin with clavulanate potassium 10 228.5 $ 8.64
Diclofenac 100 50 $ 31.65
Doxycycline 12 25 $ 18.22
Furosemide 4 10 $ 1.82
Metoclopramide 2 5 $ 0.54
Morphine 20 10 $ 9.11
Omeprazole 25 20 $ 8.92
Resource CPT Code Cost Source
CT Scan 71250 $212.98
Resource-based relative value scaleConsultant Visit 99214 $106.83
Resource CPT Code Cost Source
Radiotherapy preparation 77301 $ 1990.35
Resource-based relative value scaleRadiotherapy delivery 77418 $ 405.55
Hospitalization Cost per hospitalization
(mean)
Average length of
stay (Mean days)
Source
Hospitalization $ 12799.39 6.1 Hospital charges from HCUPnet (2013). Inﬂated from 2011 $US to 2013 $US
using the medical care component of the Consumer Price Index (US Bureau of
Labor Statistics, 2013).
Description Cost Source
Terminal Care $ 27755 Cancer end-of-life costs from Chastek et al. (2012) [27]. Estimated as the costs for the last month of life. Costs include those for
acute inpatient care, hospice, ER visits, radiation, ofﬁce visits, hospital outpatient procedures, and “other”. Excluded are
reported costs for chemotherapy, ESAs, and G-CSFs to avoid potential double counting, as it is assumed those are captured in
post-progression therapies. Inﬂated from 2009 $US to May 2013 $US using the medical care component of the Consumer Price
Index (US Bureau of Labor Statistics, 2013).
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Table 4
Cost of treatment and cost-effectiveness results.
Comparator Acquisition
costs:
Induction
Administration
costs:
Induction
Acquisition
costs:
Maintenance
Administration
costs:
Maintenance
Long term
follow up
costs
Adverse
event costs
Post
discontinuation
therapy costs
Total costs
I: Cis +Gem - M: BSC $1181.15 $3006.06 $176.02 $0 $30867.70 $13660.83 $13728.40 $62620.16
I: Carb +Pac - M: BSC $447.41 $1528.25 $154.13 $0 $30689.96 $16478.74 $15756.42 $65054.91
I: Cis +Gem - M: Erlotinib $842.88 $2145.13 $18536.43 $0 $31215.44 $14724.19 $4508.80 $71972.89
I: Carb +Pac - M: Erlotinib $393.84 $1345.26 $16227.08 $0 $30996.16 $17463.97 $12619.82 $79046.14
I: Cis + Pem - M: BSC $27539.98 $1713.68 $200.94 $0 $31293.67 $13800.29 $12098.98 $86647.53
I: Carb +Pac - M: Pemetrexed $393.84 $1345.26 $32573.69 $1368.10 $31659.06 $18053.20 $13026.76 $98419.91
I: Cis +Gem - M: Pemetrexed $842.88 $2145.13 $36808.84 $1545.98 $31961.56 $15306.68 $13421.52 $102032.59
I: Cis + Pem - M: Pemetrexed $19874.99 $1236.72 $34620.60 $1454.07 $32084.71 $15454.16 $11940.65 $116665.91
I: Bev+Carb+Pac - M: Bev $35735.79 $1966.07 $29556.05 $1002.96 $31471.29 $20159.77 $15596.30 $135488.23
Comparator Total LYs Incremental LYs Total Costs Incremental costs ICER
I: Cis +Gem - M: BSC 1.05 Referent $62620.16 Referent Referent
I: Carb +Pac - M: BSC 1.00 -0.04 $65054.91 $2435 Dominated
I: Cis +Gem - M: Erlotinib 1.12 0.08 $71972.89 $9353 $121425
I: Carb+Pac - M: Erlotinib 1.08 0.03 $79046.14 $16426 Dominated
I: Cis + Pem - M: BSC 1.22 0.18 $86647.53 $24027 $148994
I: Carb+Pac - M: Pemetrexed 1.19 0.14 $98419.91 $35800 Dominated
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OI: Cis +Gem - M: Pemetrexed 1.24 0.20
I: Cis + Pem - M: Pemetrexed 1.38 0.33
I: Bev+Carb+Pac - M: Bevacizumab 1.17 0.12
he amount of uncertainty around this point estimate; increased
pread indicates increased uncertainty.[17]
.8. Validation
The originalmodel and US adaptationwere externally reviewed
nd validated by Medical Decision Modelling (MDM), Inc.
Indianapolis, IN) in accordance with International Society for
harmacoeconomics and Outcomes Research (ISPOR) Research
ractices guidelines [18,19].
. Results
The base case results found overall costs ranged from $62,620
or cisplatin + gemcitabine followed by (→) BSC, to $135,488
or bevacizumab, carboplatin and paclitaxel→bevacizumab
aintenance (Table 4). As expected, the comparators with the
SC maintenance are among the cheapest and the most expen-
ive regimens were the bevacizumab triplet and pemetrexed+
isplatin induction→pemetrexed continuation maintenance.
able 5
ne-way sensitivity analyses.
Comparators Weibull OS, Log-logistic
PFS
Log-logistic OS,
Log-logistic PFS
I: Cis +Gem - M: BSC Referent Referent
I: Carb +Pac - M: BSC Dominated Dominated
I: Cis +Gem - M: Erlotinib Extended dominance Extended dominance
I: Carb +Pac - M: Erlotinib Dominated Dominated
I: Cis + Pem - M: BSC $141929 $81223
I: Carb+Pac - M: Pemetrexed Dominated Dominated
I: Cis +Gem - M: Pemetrexed Extended dominance Extended dominance
I: Cis + Pem - M: Pemetrexed $222375 $107856
I: Bev+Carb+Pac - M: Bev Dominated Dominated
Comparators 5 year time horizon No vial wastag
I: Cis +Gem - M: BSC Referent Referent
I: Carb +Pac - M: BSC Dominated Dominated
I: Cis +Gem - M: Erlotinib $122093 $118360
I: Carb+Pac - M: Erlotinib Dominated Dominated
I: Cis + Pem - M: BSC $150116 $135679
I: Carb+Pac - M: Pemetrexed Dominated Dominated
I: Cis +Gem - M: Pemetrexed Extended dominance Extended dom
I: Cis + Pem - M: Pemetrexed $197262 $180911
I: Bev+Carb+Pac - M: Bev Dominated Dominated$102032.59 $39412 Extended dominance
$116665.91 $54046 $191270
$135488.23 $72868 Dominated
The regimens associated with the greatest gain in total life
years (LY) were pemetrexed+ cisplatin induction→pemetrexed
continuation maintenance (1.38 LY), cisplatin + gemcitabine→
pemetrexed switch maintenance (1.24 LY), and pemetrexed+
cisplatin induction only (1.22 LY). Depending on the speciﬁc
cost-effectiveness threshold used by a decision-maker, the
cost-effective treatment sequence may include gemcitabine +
cisplatin (the referent comparator) and the studied regimens
of gemcitabine + cisplatin induction→ erlotinib maintenance
(ICER=$121,425), pemetrexed+ cisplatin induction without
maintenance (ICER=$148,994), or pemetrexed+ cisplatin→
continuation pemetrexedmaintenance (ICER=$191,270). All other
comparators are dominated with the exception of gemcitabine +
cisplatin→pemetrexed, which is extendedly dominated (Table 4).
3.1. Sensitivity analysesThe results remained consistent (<$20,000 per LY differ-
ence in the ICER) for the majority of sensitivity analyses
(Table 5). The ICER increased more than $20,000 per LY for
Induction ineligible
50% trt effect
Induction ineligible
100% trt effect
Pooled HR for Pem
maintenance
Referent Referent Referent
Dominated Dominated Dominated
$121425 $121425 $121425
Dominated Dominated Dominated
$148995 $149178 $148994
Dominated Dominated Dominated
Extended dominance Extended dominance Dominated
$190534 $191078 $169526
Dominated Dominated Dominated
e Treatment effect turn off FDA-approved comparators
Referent Referent
Dominated –
$128204 $121425
Dominated –
$158935 $148994
Dominated –
inance Extended dominance Extended dominance
$226495 $191270
Dominated Dominated
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emetrexed+ cisplatin→ cisplatin when the choice of baseline
arametric equationwas changed such that aWeibull functionwas
sed to estimate OS baseline risk and log-logistic used to estimate
FS baseline risk.When log-logisticwas chosen for bothOS andPFS,
he ICER fell for pemetrexed+ cisplatin induction→pemetrexed
aintenance and for pemetrexed+ cisplatin induction→BSC;
owever, this may be implausible due to the OS curves having long
ails in this scenario. Using the pooled hazard ratio (HR) for peme-
rexed maintenance instead of the PARAMOUNT and JMEN data
esulted in a lower ICER for pemetrexed+ cisplatin→pemetrexed
ersus pemetrexed+ cisplatin→BSC. Turning the treatment effect
ff at 32 months for induction and 34 months for maintenance
ncreased the ICERs for all comparators on the cost-effectiveness
rontier. Changing the efﬁcacy and survival assumptions had the
reatest impact on the results of the CEA.
The results of the probabilistic sensitivity analyses are provided
n Fig. 1. The cost-effectiveness plane demonstrates each com-
arator’s incremental costs against the incremental LYs from the
eferent comparator, gemcitabine + cisplatin induction→BSC and
re consistent with the primary ﬁndings.
. Discussion
In this study, efforts were made to primarily rely on the data
rom a number of clinical trials, as well as incorporating costs for
he post-treatment period from non-clinical trial sources to reﬂect
ractice patterns and costs in the US so as not to limit the inter-
retation of results to a clinical trial setting. However, the ﬁndings
hould be considered in the context of the assumptions made in
he model.
Across all studied treatment strategies, only three regimens
ere found to be neither dominated nor extendedly dominated
e.g. that provided sufﬁcient value for a decision maker to con-
ider the costs). These three regimens are gemcitabine + cisplatin
ollowed by erlotinib switch maintenance, pemetrexed+ cisplatin
ithoutmaintenance therapy, andpemetrexed+ cisplatin followed
y pemetrexed continuation maintenance. The bevacizumab-
ased treat-to-progression (e.g. maintenance) regimen was
ominated.sitivity analysis.
Eachof the treatment strategies in this analysis of various induc-
tion and maintenance treatment sequences may be considered
in terms of health care value for the decision maker, depending
on their willingness to pay for improved outcomes. While both
bevacizumab and pemetrexed continuation maintenance regi-
mens demonstrated efﬁcacy, the bevacizumab regimen was more
expensive and as a result, was dominated. Outcomes were the
most favourable for the pemetrexed+ cisplatin→pemetrexed con-
tinuation maintenance regimen, but the costs were greater than
other potentially cost-effective treatments. In addition to the
personal values and preferences of a patient during the treat-
ment decision making process, trade-offs must also be made in
terms of costs and beneﬁts when selecting the optimal treat-
ment strategy. If a no-treatment option were a valid alternative
for patients able to receive chemotherapy, the referent regi-
men may have demonstrated value; however, this analysis was
not conducted due to the restriction to relevant comparators in
the U.S.
None of the treatment strategies fell below typical thresholds of
cost-effectiveness that are often used outside of the US, although
the concept of thresholds remains an area of signiﬁcant contro-
versy [20]. The referent was demonstrated to be cost effective in
the UK health system [28], but it is unknown if this would have
been below these thresholds in the US as a no-treatment option
was not considered a viable treatment alternative and these calcu-
lationswere not performed. In the US, there is no deﬁned threshold
value to determine what is cost effective and in law it is prohibited
for Department of Health and Human Services decision making
to use such a threshold via the Patient Protection and Affordable
Care Act (PPACA) of 2010 [21]. However, a range of arbitrary val-
ues have been used to gauge value and there have been ranges of
ICER thresholds suggested (e.g. $50,000, $100,000 and $200,000)
as an aid to decision making rather than being recommended as
deﬁnitive boundaries, depending on the context of the health care
decision being made [22].
Cost-effectiveness analysis is one tool for a decision maker
in the evaluation between alternatives for patient care. Cohort-
level cost and outcome analyses are not designed to be a single
source of information to fully support or negate any treatment
option, but rather as additional information that can supplement
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linical trial andotherdataandsharedclinicaldecisionmaking. This
ost-effectiveness analysis was designed from a third-party payer
erspective, as such, the individual patient costs, such as time lost
rom work, caregiver time and resources, were not included and
ay be considered by a decision maker.
ISPOR has outlined a number of key components of good
esearch practices with regard to cost-effectiveness analy-
es and economic modelling [19,23]. This cost-effectiveness
odel followed these guidelines throughout the process from
onceptualization to ﬁnalization, in an attempt to ensure trans-
arency in the methodology and clarity in the approach so that
he results could be of value for decision making. Economic mod-
ls are often limited by the complexity and details underlying the
ork, which inhibits the ability of the decision maker to consider
he information as part of the body of knowledge related to eval-
ating various treatment strategies. While every effort was made
o provide details of the model and its assumptions, there are both
trengths and inherent limitations when using randomized clinical
rial (RCT) data to measure cost effectiveness [16]. The strengths
f using RCT data in this study include unbiased estimates of treat-
ent effect, more robust follow up data to ensure accurate survival
utcomes, sufﬁcientpower todetect both small yet clinicallymean-
ngful differences between comparators, low rates of missing data,
nd the ability to base the analysis on outcomes that are meaning-
ul to decision makers. However, external validity of this model is
educed if the trial population characteristics differ from patients
n the population of interest to a decisionmaker. Therewas limited
ata collection following discontinuation of the study intervention
e.g. such as health care resource utilization that occurs post-study
iscontinuation), and there is the risk of potential artiﬁcial resource
tilization patterns that occurred during study participation due
o study requirements for care that may differ from typical clini-
al practice settings. While attempts were made to use data to ﬁll
hese gaps that best match real world practice patterns, each of
hese limitations may reduce the external generalizability of these
ndings.
It is important to note that no one source of data is sufﬁciently
omprehensive to avoid all potential limitations. The necessary
ssumptions have been made transparent for the reader to deter-
ine the applicability of this study to their own clinical practice
etting.
Providers and patients have choices for care that should be
ased on evidence supporting the beneﬁts a patient is expected
o receive. Based on this study, the choices representing poten-
ial value in terms of the cost of care and improved survival
utcomes may include gemcitabine + cisplatin (the referent com-
arator) and the studied sequences of gemcitabine + cisplatin→
rlotinib maintenance, cisplatin +pemetrexed induction only, or
isplatin +pemetrexed→pemetrexed continuation maintenance.
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